This is a complication that can happen when you have kidney disease. It affects your bones, causing them to become weak or develop abnormally. It's caused by problems with vitamin D and parathyroid hormone levels.
Every report comes from a Lived member, sent anonymously.
Have you tried Sevelamer for Chronic Kidney Disease-Mineral and Bone Disorder?
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a set of problems with minerals, hormones, bones and blood vessels that develops when chronic kidney disease (CKD) leaves the kidneys unable to keep calcium and phosphorus in balance. Over time, that imbalance can weaken or misshape bones and cause calcium deposits to build up in the walls of blood vessels and heart valves. The bone part of the disorder is often called renal osteodystrophy. CKD-MBD is very common in people with CKD and becomes more pronounced as kidney function declines. It is found in almost everyone with kidney failure who is on dialysis or has had a kidney transplant. In adults it is usually silent for years, which is why it is tracked through regular blood tests. When it does cause symptoms, they include bone and joint pain and bones that break more easily. Children are affected differently because their bones are still growing: they can grow more slowly than expected or develop bowed legs, sometimes called renal rickets, even at earlier stages of kidney disease.
The cause is the kidney disease itself. Healthy kidneys remove extra phosphorus from the blood and convert vitamin D into its active form, calcitriol, which helps the body absorb calcium from food. As kidneys lose function, phosphorus builds up and calcitriol falls, so blood calcium tends to drop. The parathyroid glands, four small glands in the neck that are separate from the thyroid, respond by releasing more parathyroid hormone (PTH). PTH restores blood calcium by drawing it out of bone. When this response continues for years, a pattern called secondary hyperparathyroidism, it weakens the skeleton. Another hormone made by bone, fibroblast growth factor 23, also rises and adds to the imbalance. The disorder worsens as kidney function declines, so it is most severe in people on dialysis. A diet high in phosphorus, low vitamin D stores, and a dialysis schedule or medicines that do not fully control phosphorus can all push the numbers further out of range. These are the factors care teams look at first when PTH keeps rising.
CKD-MBD is identified and followed mainly through blood tests rather than symptoms. The key measurements are calcium, phosphorus, PTH and alkaline phosphatase, an enzyme that rises when bone is being broken down and rebuilt quickly. A vitamin D test (25-hydroxyvitamin D, the stored form) may be checked as well. International kidney guidelines recommend starting these tests once CKD reaches stage 3, the middle of five stages based on how well the kidneys filter blood, and in children from stage 2. Testing becomes more frequent as kidney function falls: for calcium and phosphorus, roughly every 6 to 12 months in stage 3, and every 1 to 3 months in stage 5 or on dialysis. These numbers are interpreted together and over time. Because they move with diet, dialysis and medicines, a single abnormal result usually matters less than a steady trend. PTH is a good example: there is no agreed ideal level before dialysis, so clinicians watch for a level that keeps rising or stays above the lab's normal range. For people on dialysis, guidelines suggest keeping PTH at roughly 2 to 9 times the upper limit of the lab's normal range, because levels far above or below that suggest bone turnover that is too fast or too slow. Other tests are used when the answer would change treatment. A bone density scan (DXA) can help estimate fracture risk. An X-ray of the abdomen or an ultrasound of the heart (echocardiogram) can show calcium deposits in blood vessels or heart valves. A bone biopsy, which takes a small sample of bone, is rarely needed. In children, height or length is measured regularly to catch slowed growth early.
Treatment aims to bring phosphorus back toward normal, avoid high calcium and keep PTH from climbing too high or falling too low, with the goal of protecting both bones and blood vessels. Because each treatment shifts more than one of these values, choices are adjusted together based on repeated blood tests. Lowering phosphorus usually starts with food. Many foods contain phosphorus, but processed and packaged foods such as lunch meats and canned or boxed foods often contain added phosphorus as a preservative, so ingredients containing "phos" on a label are worth limiting. A kidney dietitian can help make these changes workable. When diet is not enough, phosphate binders are taken with meals and snacks to trap phosphorus in the gut so less is absorbed. Calcium-based binders such as calcium acetate work well, but guidelines suggest limiting their dose in adults to avoid adding too much calcium. Non-calcium binders such as sevelamer (Renvela) avoid that problem; in people on dialysis, low-certainty evidence suggests sevelamer may lower the risk of death compared with calcium-based binders. Constipation, nausea and the number of pills are the common trade-offs. For people on dialysis, longer or more frequent sessions remove more phosphorus. Controlling PTH starts with correcting low vitamin D stores and high phosphorus. In adults before dialysis, prescription active vitamin D (calcitriol or similar medicines) is generally reserved for severe, worsening hyperparathyroidism in stages 4 and 5, because it can raise calcium and phosphorus. On dialysis, the options are active vitamin D, a calcimimetic, or both. Calcimimetics such as cinacalcet (Sensipar) make the parathyroid glands more sensitive to calcium so they release less PTH. For kidney-related hyperparathyroidism, cinacalcet is approved only for adults on dialysis, partly because it can lower blood calcium too far, so calcium is checked regularly after starting or changing the dose. If medicines cannot bring very high PTH under control, a surgeon can remove one or more of the parathyroid glands (parathyroidectomy). Osteoporosis medicines are used as in the general population for people with early CKD. In more advanced CKD with abnormal mineral tests, the choice is more individual: it depends on how abnormal the mineral tests are and how quickly kidney function is changing, and a bone biopsy is sometimes considered first. One osteoporosis injection, denosumab (Prolia), can cause severe, sometimes dangerous drops in blood calcium in people with advanced CKD or on dialysis, especially when CKD-MBD is present, so it is started only after mineral levels are checked and with close calcium monitoring overseen by the kidney team. Children with slowed growth may be offered growth hormone once nutrition and mineral levels are addressed. A kidney transplant often improves the mineral balance, but bone health is still monitored afterward.
CKD-MBD lasts as long as the kidney disease does and generally becomes more involved as kidney function declines. For many people, daily life with it centers on routine: taking binders with every meal, paying attention to phosphorus in food, completing dialysis sessions, and having blood drawn on a regular schedule. Lab values often drift, and medicines are frequently adjusted, so a change in the plan usually reflects normal fine-tuning rather than failure. Treatment reliably improves the blood test numbers, but the evidence that this translates into fewer heart problems, fractures or deaths is less certain than people often assume. Studies of phosphate binders have not shown a clear reduction in heart-related deaths or vessel calcification compared with usual care, and a large trial testing whether cinacalcet reduced deaths and major heart and blood vessel events in people on dialysis did not show a clear benefit, although later analyses suggested it might help some people. This is why care is guided by overall trends and individual risk rather than chasing every number. The burden is real: the pill count can be high, food choices narrow, and side effects add to the daily load. A kidney dietitian, a pharmacist reviewing the full medicine list, and open discussion about which pills matter most can make the routine easier to sustain. After a transplant, calcium and phosphorus are checked at least weekly at first until they settle, and bone loss in the first year may need its own treatment.
If you have stage 3 kidney disease or beyond and have not had calcium, phosphorus and PTH checked, ask your care team about it. Tell your kidney team if you develop new or worsening bone or joint pain, break a bone after a minor fall, or find the binder routine or diet too hard to keep up, since there are often alternatives. Contact your care team right away if you take a medicine that can lower calcium, such as cinacalcet or denosumab, or have recently had parathyroid surgery, and notice tingling or numbness around the mouth or in the fingers, or muscle aches, cramps or spasms, which can signal low calcium. Hard, painful patches of skin or skin sores that do not heal, particularly in someone on dialysis, also need prompt review by the kidney team, because they can be a sign of calciphylaxis, a rare but serious complication in which calcium deposits block small blood vessels in the skin.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Chronic Kidney Disease-Mineral and Bone Disorder is like, what's helped you, or ask the community a question.